Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

Reiniš, M, Šímová, J, Indrová, M, Bieblová, J, Bubeník, J.

. 2007 ; 30 (5) : 1247-1251.

Jazyk angličtina Země Řecko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10003263
E-zdroje Online

NLK Free Medical Journals od 2006 do Před 1 rokem

Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneic C57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression.

000      
00000naa 2200000 a 4500
001      
bmc10003263
003      
CZ-PrNML
005      
20120709213945.0
008      
100209s2007 gr e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Reiniš, Milan $7 xx0083033
245    10
$a CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours / $c Reiniš, M, Šímová, J, Indrová, M, Bieblová, J, Bubeník, J.
314    __
$a Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague 6, Czech Republic
520    9_
$a Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneic C57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression.
650    _2
$a financování organizované $7 D005381
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a CpG ostrůvky $7 D018899
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a geny MHC třídy I $7 D005805
650    _2
$a lidský papilomavirus 16 $x metabolismus $7 D052162
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a reziduální nádor $x farmakoterapie $7 D018365
650    _2
$a nádory $x genetika $x terapie $x virologie $7 D009369
650    _2
$a oligonukleotidy $x chemie $x terapeutické užití $7 D009841
650    _2
$a recidiva $7 D012008
700    1_
$a Šímová, Jana $7 xx0119399
700    1_
$a Indrová, Marie $7 xx0069868
700    1_
$a Bieblová, Jana $7 xx0127729
700    1_
$a Bubeník, Jan, $d 1940- $7 jk01020086
773    0_
$w MED00002350 $t International journal of oncology $g Roč. 30, č. 5 (2007), s. 1247-1251 $x 1019-6439
910    __
$a ABA008 $b x $y 8
990    __
$a 20100114162108 $b ABA008
991    __
$a 20120709213920 $b ABA008
999    __
$a ok $b bmc $g 709192 $s 572005
BAS    __
$a 3
BMC    __
$a 2007 $b 30 $c 5 $d 1247-1251 $i 1019-6439 $m International journal of oncology $x MED00002350
LZP    __
$a 2010-b1/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...